
Does TGF-beta blocker treat pancreatic cancer?
Checked
Posts say that drugs blocking TGF-beta can treat pancreatic cancer.
It is not proven that TGF-beta blocker treats pancreatic cancer.
What studies show
As of , no study proves that TGF-beta blocker treats pancreatic cancer. We found 155 published papers on TGF-beta blocker and pancreatic cancer. They were published between 2016 and 2026. 8 of them are studies in people. 2 of them followed or compared people without deciding who got it (observational studies). Such studies can show a link, but not that one thing causes the other. At least 478 people took part. 4 of them were fair tests in which chance decided who got it and who did not. 62 were studies in animals, and 45 were only in cells in the lab. 15 papers are reviews that sum up other studies.
Trials in people
One trial added the TGF-beta drug NIS793 to chemotherapy and compared it with chemotherapy alone. The drug reached its target, but patients did no better than with chemotherapy alone. Another trial of galunisertib plus chemotherapy was described as effective, but cancers can resist it. In 88 people, a blood pressure drug added to chemotherapy did not help them live longer.
Other studies in people
51 people with bile duct or pancreatic cancer got a drug blocking TGF-beta and another protein. In the pancreatic group, tumours shrank in 15 in 100 people. These people lived a median of 5.3 months, and there was no comparison group. Other studies only found links between TGF-beta and the disease, not effects of treatment.
Reviews
A 2024 review says blocking TGF-beta reduced resistance to treatment when combined with other treatments. A 2023 review calls TGF-beta blocking a strategy that has emerged recently. A 2022 review notes that in mice it reduced weight and muscle loss, which is a separate question from shrinking the tumour.
In animals
In mice, TGF-beta blocking reduced scar-like tissue around pancreatic tumours. In mice, other approaches that lowered TGF-beta slowed tumour growth or worked better than chemotherapy alone. Results in animals do not always hold in people.
In the lab
Studies in cells show TGF-beta affects how tumour cells spread and how nearby support cells behave. A 2025 study in cells and mice made pancreatic tumours in mice respond better to another immunotherapy.
What this means for you
Our verdict: Unproven.
In people, one trial of a TGF-beta drug found no benefit, and another study had no comparison group. Results in mice and cells look promising, but they have not been confirmed in people, so the claim is unproven.
Do not stop or change your treatment because of a story about TGF-beta blocker. A study in people is not proof that it helps you. If you are thinking about TGF-beta blocker, talk to your care team first.
This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.
We searched 18 scientific databases for research from the last 10 years (since 17 Nov 2016).
Sources
- Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study. Clin Cancer Res 2026. Randomised trial. PubMed
- TGF-β-YY1 signaling as a key driver of immune evasion in pancreatic cancer: Therapeutic implications. Cytokine Growth Factor Rev 2026. Review. PubMed
- TGF-β-Targeting Platinum(IV) Prodrugs Remodel Tumor Microenvironment of Pancreatic Cancer via Antifibrotic and Immunomodulatory Effects. J Med Chem 2026. In animals. PubMed
- TGFβ Blockade by Inhibition of Enolase-1-Mediated Plasmin Targets Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma. Oncol Res 2026. In animals. PubMed
- Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer. Cancer Res 2026. In animals. PubMed
- Sequential cryoablation enhances chemotherapeutic efficacy in pancreatic cancer by downregulating TGF-β mediated fibrosis in the sub-lethal zone. J Therm Biol 2026. In animals. PubMed
- Fibroblasts hold the key to TLS formation. Immunity 2026. Other paper. PubMed
- Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates. Signal Transduct Target Ther 2026. Other paper. PubMed
- Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study). Cancer 2025. Randomised trial. PubMed
- Mitochondrial-targeted photodynamic therapy combined with TGF-β inhibition potentiates anti-PD-1 therapy in pancreatic ductal adenocarcinoma. J Nanobiotechnology 2025. In the lab. PubMed
- IGF2BP3 regulates EMP1 stability in an m6A-dependent manner and activates the TGF-β pathway to promote pancreatic cancer invasion. Cell Death Dis 2025. In the lab. PubMed
- The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Cancer Res 2025. In the lab. PubMed
- Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Cancer Res 2024. Randomised trial. PubMed
- Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. Signal Transduct Target Ther 2024. Study in people. PubMed
- TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance. Clin Cancer Res 2024. Review. PubMed
- Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer. Curr Drug Targets 2023. Review. PubMed
- Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. J Immunother Cancer 2023. Randomised trial. PubMed
- Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics. Cells 2022. Review. PubMed
- Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Pancreas 2020. Observational study in people. PubMed
- Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res 2019. Study in people. PubMed
- Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. Clin Cancer Res 2019. Observational study in people. PubMed
Frontlight Community
Share what you saw, tried or were told about this claim, and read what others went through. Posts are not medical advice: ask your doctor about your own treatment.
Be the first to share your experience or your question about this claim
You need a Frontlight account with a verified e-mail address to comment.